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Tetralogy of FallotThe Sonic hedgehog (Shh)-null mouse was initially described as a phenotypic mimic of Tetralogy of Fallot
with pulmonary atresia (Washington Smoak, I., Byrd, N.A., Abu-Issa, R., Goddeeris, M.M., Anderson, R., Morris,
J., Yamamura, K., Klingensmith, J., and Meyers, E.N. 2005. Sonic hedgehog is required for cardiac outﬂow tract
and neural crest cell development. Dev. Biol. 283, 357–372.); however, subsequent reports describe only a
single outﬂow tract, leaving the phenotype and its developmental mechanism unclear. We hypothesized that
the phenotype that occurs in response to Shh knockdown is pulmonary atresia and is directly related to the
abnormal development of the secondary heart ﬁeld. We found that Shh was expressed by the pharyngeal
endoderm adjacent to the secondary heart ﬁeld and that its receptor Ptc2 was expressed in a gradient in the
secondary heart ﬁeld, with the most robust expression in the caudal secondary heart ﬁeld, closest to the Shh
expression. In vitro culture of secondary heart ﬁeld with the hedgehog inhibitor cyclopamine signiﬁcantly
reduced proliferation. In ovo, cyclopamine treatment before the secondary heart ﬁeld adds to the outﬂow
tract reduced proliferation only in the caudal secondary heart ﬁeld, which coincided with the region of high
Ptc2 expression. After outﬂow tract septation should occur, embryos treated with cyclopamine exhibited
pulmonary atresia, pulmonary stenosis, and persistent truncus arteriosus. In hearts with pulmonary atresia,
cardiac neural crest-derived cells, which form the outﬂow tract septum, migrated into the outﬂow tract and
formed a septum. However, this septum divided the outﬂow tract into two unequal sized vessels and
effectively closed off the pulmonary outlet. These experiments show that Shh is necessary for secondary
heart ﬁeld proliferation, which is required for normal pulmonary trunk formation, and that embryos with
pulmonary atresia have an outﬂow tract septum.© 2009 Elsevier Inc. All rights reserved.IntroductionIn the bilateral cardiac ﬁelds, Nxk2.5 expression is maintained in
the second heart ﬁeld after the ﬁrst heart ﬁeld has down-regulated
Nxk2.5 and formed the initial heart tube (Prall et al., 2007). Within
this second heart ﬁeld, the secondary heart ﬁeld is a speciﬁc region
that is located in the pharyngeal splanchnic mesoderm caudal to the
outﬂow tract (Waldo et al., 2001). During heart looping, the outﬂow
tract is displaced caudally with respect to the pharyngeal arches, and
the secondary heart ﬁeld cells nearest the outﬂow tract migrate into
the outﬂow tract (Waldo et al., 2001).
The secondary heart ﬁeld differentiates into ﬁrst cardiac and then
smooth muscle. Outﬂow tract myocardium is added over a 24-hour
period in chick, spanning Hamburger Hamilton (HH) stages 14
through 18. This myocardium ultimately incorporates into the
ventricles, forming the subvalvular outlets. Smooth muscle is
generated between HH 18 and HH 22 and forms the tunica media atC 27710, USA. Fax:+1919 668
l rights reserved.the base of the arterial trunks (Waldo et al., 2005a). The outﬂow tract
is septated by cardiac neural crest-derived cells, forming aortic and
pulmonary outlets, and the aorta subsequently becomes “wedged”
between the atrioventricular valves, behind the pulmonary trunk
(Kirby, 2007).
Ablation of the right secondary heart ﬁeld progenitors causes
defects in both the subpulmonary myocardium and the smooth
muscle junction of the coronary arteries with the aorta (Ward et al.,
2005). These phenotypes are consistent with the human congenital
heart defect Tetralogy of Fallot.
Tetralogy of Fallot affects 9–14% of children born with congenital
heart defects and affects four of every 10,000 live births each year
(Rosamond et al., 2007; Hoffman and Kaplan, 2002). Several genes
have been linked to Tetralogy of Fallot, including transcription factor
Tbx1. The Tbx1-null mouse shows diminished proliferation in the
secondary heart ﬁeld and a solitary outﬂow vessel (Xu et al., 2004).
Sonic hedgehog (Shh) is among the genes that interact with Tbx1
(Garg et al., 2001), and the Shh-null mouse also has arterial pole
defects, including a phenocopy of Tetralogy of Fallot with complete
pulmonary atresia (Washington Smoak et al., 2005). Interestingly,
subsequent analyses of mice lacking Shh in the pharyngeal endoderm
Table 1
Quantitative RT-PCR primers.
Gene Primers Size (bp) Efﬁciency
Ptc1 Forward: 5′ AAGTGTAGCCCTTACATCTATCAG 3′ 100 2.05
Reverse: 5′ CAACTGCTGCTTGGAGTG 3′
Ptc2 Forward: 5′ CTTCTACAGCCCTTGCTC 3′ 75 2.26
Reverse: 5′ GGCATGGTTGTCGTTGG 3′
HPRT Forward: 5′ CTGTAATGATCAGTCAACTGGA 3′ 179 1.91
Reverse: 5′ ACCAACAAACTGGCCAC 3′
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arteries and impaired cardiac neural crest cell migration (Goddeeris et
al., 2007, 2008). The single outﬂow vessel was not classiﬁed. This
study identiﬁed apoptosis in the pharyngeal endoderm and splanch-
nic mesoderm as a potential cause of these defects; however,
apoptosis was evaluated at a stage that was too late to identify
aberrant apoptosis speciﬁcally in the secondary heart ﬁeld. As such,
the arterial pole defects that occur in the absence of Shh signaling
remain unidentiﬁed, and the mechanism through which these defects
occur is unknown. We hypothesized that Shh speciﬁcally affected the
secondary heart ﬁeld.
We ﬁrst determined that Shh mRNA was expressed in the
pharyngeal endoderm adjacent to the secondary heart ﬁeld;
however, receptor and downstream target Patched 2 (Ptc2) was
expressed in the secondary heart ﬁeld, conﬁrming that the
secondary heart ﬁeld responds to Shh signaling. Ptc2 expression
formed a gradient, with lowest expression levels adjacent to the
outﬂow tract and highest expression in the caudal secondary heart
ﬁeld. When secondary heart ﬁeld explants were incubated with
Shh inhibitor cyclopamine, proliferation was reduced. In ovo,
cyclopamine reduced proliferation only in the region of the
secondary heart ﬁeld that showed intense Ptc2 expression. Arterial
pole defects, including pulmonary atresia and stenosis, persistent
truncus arteriosus (PTA), and abnormal patterning of the aortic
arch arteries, were induced in a stage-dependent manner. Im-
portantly, cardiac neural crest-derived cells migrated into the
outﬂow tract cushions and formed a septum in embryos with
pulmonary atresia, albeit the septum appeared to close off the
pulmonary outlet, leaving a single outﬂow vessel. In addition,
coronary artery abnormalities were seen in one-third of treated
embryos. These data support a role for Shh in maintaining
proliferation in a subset of secondary heart ﬁeld progenitors to
allow an optimal number of myocardial and smooth muscle cells to
migrate to the arterial pole.
Materials and methods
Embryos
Fertilized Ross Hubert chick eggs (Gallus domesticus, Pilgrim's
Pride Hatchery, Siler City, NC) were incubated for 1–9 days, and
Coturnix quail eggs (Coturnix coturnix, Ozark Egg Co, Stover, MO)were
incubated for 1–2 days; both were maintained at 37 °C and 70%
humidity. Embryos were staged according to Hamburger and
Hamilton (1951).
Antibodies and immunohistochemistry
The following primary antibodies were used: QCPN and MF20
(Developmental Studies Hybridoma Bank, Iowa City, IA); anti-BrdU
(Roche, Indianapolis, IN); and SM22-α (Abcam, Cambridge, MA).
Antibodies were visualized using AlexaFluor 488 or AlexaFluor 568
(Molecular Probes, Carlsbad, CA). QCPNwas used as described byWaldo
et al. (1998); all other antibodies followed the protocol described by
Waldo et al. (1996).
In situ hybridization
Shh and Ptc2 plasmids were generously provided by Cliff Tabin.
Embryos were harvested at HH 15–16 in DEPC-treated 4% parafor-
maldehyde. In situ hybridization was carried out as described by
Wilkinson (1992). Control and drug-treated embryos were developed
in alkaline-phosphatase detection solution for the same length of
time. After whole mount photography, embryos were parafﬁn
embedded and sectioned at 10 μm. Some sections were counter-
stained with eosin.Secondary heart ﬁeld isolation
At HH 14, eggs were windowed, and 1.5 μl of 0.25 μM DiI
(Molecular Probes) was pipetted into the pericardial cavity. After the
dye penetrated the outer cell layer, the splanchnic mesoderm and
underlying ventral pharyngeal endoderm between the outﬂow and
inﬂow tracts were removed. To separate the splanchnic mesoderm
comprising the secondary heart ﬁeld from the underlying endoderm,
the tissue was digested in 0.25% trypsin and 2.5% pancreatin (1:1) for
5min. Isolated secondary heart ﬁeldmesodermswere identiﬁed using
DiI ﬂuorescence and placed in 10% fetal bovine serum in Liebovitz
mediumwith varying concentrations of cyclopamine (Sigma, St. Louis,
MO). These explants express heart ﬁeld marker Isl1 (R. Subramanian,
personal communication) and will differentiate into both myocar-
dium and smooth muscle.
In ovo cyclopamine treatment
Eggs were windowed, and 10 μl of cyclopamine (0.6–1.0 μg/μl) or
PBS (control) was pipetted onto the embryo; eggs were sealed with
tape and incubated. Unless stated otherwise, embryos were treated at
HH 14. Stock cyclopamine was dissolved in 95% EtOH and diluted with
PBS. Ninety percent of the drugged embryos survived to HH 35 (10 of
11 embryos treated with 0.6 μg/μl, and 9 of 10 embryos treated with
0.8 μg/μl cyclopamine). Shell-less culture (Ward et al., 2005) was
initially used but yielded lower survival (4 of 12 embryos treated with
0.6 μg/μl, 4 of 10 embryos treated with 0.8 μg/μl, and 2 of 4 embryos
treated with 1.0 μg/μl survived to HH 35). Embryos incubated in shell-
less culture exhibited the same phenotypes as those treated in ovo and
have been included in the analysis. Three embryos (two shell-less
culture and one in ovo) that died just prior to collection and had good
tissue preservation were included, so 32 treated embryos were
collected. Embryos were harvested, photographed, ﬁxed in 10%
formalin overnight at 4 °C, parafﬁn embedded, sectioned, and stained
with hematoxylin and eosin. Because embryos treated at HH 14 with
1.0 μg/μl cyclopamine that survived to HH 35 were generally
unhealthy, they were excluded from the detailed section analysis.
Quantitative reverse transcription PCR (qRT-PCR)
To conﬁrm that cyclopamine inhibits the hedgehog pathway in
ovo, secondary heart ﬁeld explants were excised from HH 16 control
and drug-treated embryos. mRNA was then isolated using the Qiagen
RNeasy kit (Qiagen, Valencia, CA). cDNA was reverse transcribed by
incubating 30 μl mRNA, 2 μl random hexamer primers, and 1 μl dNTPs
for 5 min at 72 °C; then adding 9.5 μl 5× reaction buffer, 3 μl 0.1 M DTT,
and 1 μl RNase inhibitor and incubating for 2 min at room
temperature; and ﬁnally adding 1 μl superscript II and incubating
for 2 h at 37 °C. cDNA was stored at −20 °C.
For qRT-PCR, primers were designed for Ptc1, Ptc2, and house-
keeping gene HPRT (Table 1). Primer efﬁciency was tested over a
linear range of starting cDNA (0.5–500 ng) and calculated according to
Pfafﬂ (2004). The PCR mix consisted of 100 ng cDNA, SybrGreen, and
1 μl of each primer (10 nM each) in a total of 25 μl. cDNAwas ampliﬁed
using the following cycle parameters: 95 °C for 2 min; 40 cycles of
94 °C for 30 s, 56 °C for 20 s, and 72 °C for 30 s; and 72 °C for 10 min.
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ΔCP to the reference gene ΔCP, adjusted for primer efﬁciency (Pfafﬂ,
2004).
Secondary heart ﬁeld migration
Secondary heart ﬁeld explants were placed on a warmed stage
(LiveCell, Westminster, MD) maintained at 37 °C. To quantify cell
migration, a Nikon Eclipse TE2000-U microscope and MetaMorph
software were used to photograph the explants at the beginning and
end of a 16-hour period. At least six explants per treatment were
recorded, and relative migration indices were calculated based on
Epstein et al. (2000). The difference in explant area between the end
and the beginning of the 16-hour period was calculated and normal-
ized by dividing this difference by the explant perimeter at the end of
the 16-hour period (see Figs. 2A, B for an example). This normalization
allowed for comparisons to be made between explants of varying
sizes. Statistical signiﬁcancewas determined using unpaired Student's
t-test with equal variances.
Secondary heart ﬁeld proliferation
To measure proliferation in the secondary heart ﬁeld, both
secondary heart ﬁeld explants and whole embryos were treated
with BrdU as described in Waldo et al. (2001). Secondary heart ﬁeld
explants were treated with BrdU 24 h post-dissection, ﬁxed in
methanol, immunolabeled for BrdU and myocardium (using MF20),
and counterstained with DAPI (Molecular Probes) to visualize nuclei.
To determine the rate of proliferation and the percentage of
myocardial differentiation, at least 300 cells within the monolayer
that migrated away from each explant were counted. Explants with
less than 300 migratory cells were excluded from further analysis. A
minimum of six explants per dose was counted to calculate statistical
signiﬁcance, which was determined using unpaired Student's t-test
with equal variances.
To determine whether proliferation differences also occurred in
ovo, embryos were treated with cyclopamine or PBS at HH 14, and
mitotic indices were determined using BrdU incorporation as
described in Waldo et al. (2001). Sections were co-labeled with
MF20 and DAPI. Proliferating cells within the ﬁrst 80 secondary heart
ﬁeld cells, starting at the junction of the outﬂow tract and moving
caudally through the secondary heart ﬁeld, were counted. AlternatingFig.1. Expression of hedgehog signaling components during secondary heart ﬁeld (SHF) deve
pharyngeal clefts 2 and 3 and the foregut (A), speciﬁcally the pharyngeal endoderm (PE,
(B); however, Ptc2 is restricted to the SHF mesoderm (arrow in B) adjacent to the Shh-ex
expression of receptor and downstream target Ptc2, as observed by in situ hybridization. Em
treatment. Time allowed for color development was the same for embryos in both B and C. (D
and Ptc2 are signiﬁcantly down-regulated after CPA treatment (pb0.01 for both). Scale bar
outﬂow tract.10-μm sections were counted in 10-cell increments, and only embryos
with a secondary heart ﬁeld spanning 110 μm were analyzed. The
average proliferation per 10-cell increment was calculated in each
embryo, and at least three embryos were counted per treatment.
Statistical signiﬁcance was determined using unpaired Student's t-test
with equal variances.
India ink injections
To determine whether arch artery patterning was normal,
pharyngeal arch arteries were visualized in control and cyclopa-
mine-treated embryos between HH 17 and 29 by injecting India ink
into a vitelline vein. Ink-injected embryos were harvested, ﬁxed
overnight at 4 °C in Carnoy's, and cleared in a 1:1 methylsalicylate:
benzylbenzoate solution. To further characterize the arch artery
patterns, HH 29 embryos were washed in toluene for parafﬁn
embedding, and sections were counterstained with eosin.
Quail-chick chimeras
Quail-chick chimeras were made as described in Kirby (1988) to
observe whether cardiac neural crest-derived cells migrated into the
outﬂow tract and formed a septum after cyclopamine treatment. Host
eggs were sealed with tape and reincubated to HH 14, when they were
treated with 0.8 μg/μl cyclopamine or PBS and reincubated to either
HH 23–24 or HH 35. Embryos harvested at HH 23–24 were ﬁxed in 4%
paraformaldehyde at 4 °C overnight, and embryos harvested at HH 35
were ﬁxed in methacarn at 4 °C overnight. All embryos were parafﬁn
embedded, sectioned, and labeled with QCPN to recognize quail cells,
either the Vector Apoptag kit to recognize apoptotic cells (HH 23–24)
or muscle markers (HH 35), and DAPI.
Results
Shh expression pattern
Previous work has shown that Shh is expressed in the cerebellum,
the foregut, and the pharyngeal arches (Ingham and McMahon, 2001;
Moore-Scott and Manley, 2005); however, it is unclear whether Shh is
expressed within or near the secondary heart ﬁeld. We found Shh
mRNA expression in whole mount embryos in the caudal boundaries
of pharyngeal arches two and three and the foregut (Fig.1A). At HH 15,lopment in chick embryos. (A, A') Shh in situ hybridization at HH 15 shows expression in
A'). (B, B') Ptc2 in situ hybridization at HH 16 shows a similar wholemount pattern
pressing endoderm. (C, C') Within 12 h, cyclopamine (CPA)-treated embryos show no
bryos were treated at HH 14 and collected at HH 16. Ptc2 expression is absent after CPA
) Quantitative RT-PCR was used to analyze isolated SHF from HH 16 embryos. Both Ptc1
in C is 100 μm in B, C, and the scale bar in C' is 200 μm in A' and 100 μm in B'–C'; OFT,
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most robust in the ventral midline endoderm caudal to the outﬂow
tract (Fig. 1A'). Lateral to the midline, expression was reduced (data
not shown). Desert and Indian hedgehogs were not detected in
murine secondary heart ﬁeld and pharyngeal endoderm explants by
microarray analysis and were not analyzed further (Dyer and Kirby,
unpublished). The ability of the secondary heart ﬁeld to respond to
Shh signaling was determined using in situ hybridization to localize
Shh receptor and downstream target Ptc2. In whole mount, Ptc2
expression was similar to that of Shh mRNA in the caudal boundaries
of the pharyngeal arches and was also present in the pharynx (Fig.
1B). In addition, Ptc2 was speciﬁcally localized to the secondary heart
ﬁeld (Fig. 1B'). No expression was seen within the pharyngeal
endoderm. These expression patterns conﬁrm that the secondary
heart ﬁeld responds to Shh signaling. In addition, treating embryos
with cyclopamine abolished Ptc2 expression in the secondary heart
ﬁeld and the pharyngeal arches (Figs. 1C, C'). Quantifying this
decrease in excised HH 16 secondary heart ﬁelds using qRT-PCR
conﬁrmed that both Ptc1 and Ptc2 were signiﬁcantly decreased byFig. 2. Cyclopamine (CPA) reduces proliferation and migration in vitro. (A) Before and (B) af
explant is highlighted in red. (C, D) Explants were treated with PBS (C) or CPA (D) and labe
heart ﬁeld (SHF) mesoderm after CPA treatment. (E) Treating SHF explants with CPA reduces
hour period. The highest dose reversed the anti-proliferative effect, suggesting a narrow rannearly 10-fold (pb0.001 for both receptors, Student's t-test with equal
variances, Fig. 1D).
Response of secondary heart ﬁeld to hedgehog inhibitor cyclopamine
in vitro
To assess the effect of Shh on secondary heart ﬁeld progenitors,
secondary heart ﬁeld mesoderm was separated from Shh-expressing
pharyngeal endoderm and treated with cyclopamine. Explants were
dissected from embryos at HH 14, which coincides with the onset of
the myocardial addition to the outﬂow tract. Over a 16-hour period,
migration was reduced by 20% in cyclopamine-treated embryos
(pb0.05, Fig. 2F). To determine secondary heart ﬁeld proliferation,
the mitotic index was measured by BrdU incorporation 24 h post-
dissection. After cyclopamine treatment, secondary heart ﬁeld
proliferation was decreased by as much as 75% compared to control
explants (pb0.0001, Fig. 2E). Onlymigration and proliferation showed
a dose-dependent response to cyclopamine. Myocardial differentia-
tion normally begins around 48 h after culture, and no alteration inter images of a control explant during the 16-hour migration assay. The perimeter of the
led with BrdU (green) and DAPI (blue). Note the reduction of BrdU-positive secondary
proliferation after 24 h. (F) Treating SHF explants with CPA reduces migration over a 16-
ge of anti-proliferative signaling. Scale bar is 25 μm in C and D. ⁎p≤0.05, ⁎⁎p≤0.0001.
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ing hedgehog signaling primarily decreases proliferation, slightly
decreases migration, and does not affect myocardial differentiation.
Cyclopamine disrupts secondary heart ﬁeld proliferation in ovo
To determine whether the distinct effect of cyclopamine on
secondary heart ﬁeld proliferation in vitro also occurs in ovo, embryos
were treated with cyclopamine at HH 14, when the secondary heart
ﬁeld progenitors begin to add myocardium to the outﬂow tract.
Treated and control embryos were initially collected at HH 16 to
analyze secondary heart ﬁeld proliferation. Caudal secondary heart
ﬁeld cells were highly proliferative (Fig. 3B). As the cells migrated into
the outﬂow tract, they began to differentiate and elongate, and
proliferation decreased by nearly 50% as the cells migrated away from
the Shh-producing pharyngeal endoderm (Figs. 3A, B). Upon reaching
the myocardial outﬂow tract, proliferation nearly ceased (Fig. 3B). In
cyclopamine-treated embryos, proliferationwas visibly reduced in the
cells previously found to express high Ptc2 levels in the secondary
heart ﬁeld (Fig. 3C). Proliferation was unchanged in the cranial-most
secondary heart ﬁeld, which is further away from both the pharyngeal
Shh source and the region of secondary heart ﬁeld that expresses Ptc2.Fig. 3. Cyclopamine (CPA) treatment disrupts secondary heart ﬁeld (SHF) proliferation in ovo
Embryos were labeled with BrdU (green nuclei) at HH 16; myocardium is red. (C) Total Brd
starting at the myocardial border of the outﬂow tract (OFT; increment 1), as delineated with
mesoderm (with increment 8 being the most caudal). Between HH 15 and 17, proliferation
nearly twice the rate that is seen in the 50 cranial-most cells. Within 12 h of cyclopamine
increments 6–8); this decrease is maintained through HH 17 (pb0.05 for increments 6–8)
embryos. Scale bar is 100 μm.To determine when this proliferation decrease occurs, embryos
were analyzed from HH 15 to 18. In addition, to determine whether
there is a proliferation gradient that correlates with the Ptc2
expression gradient, proliferation was quantiﬁed by counting
proliferating secondary heart ﬁeld cells starting at the myocardium
and moving caudally in 10-cell increments. At HH 15, proliferation
was present throughout the secondary heart ﬁeld and was more
robust in the caudal portion. In treated embryos, which had been
exposed to cyclopamine for 6 h, no change in proliferation was
observed with respect to the control embryos (Fig. 3A). However,
at HH 16 and 17, proliferation did not increase in the more caudal
30 cells after cyclopamine treatment (Fig. 3A, pb0.01) and was
almost half of that which was observed in control embryos. No
signiﬁcant change in proliferation was seen within the cranial-most
50 cells of cyclopamine-treated embryos as compared to control
embryos; this region corresponds with the lowest Ptc2 expression
(see Fig. 1B). The highly proliferative region correlates with strong
Ptc2 expression, suggesting that Shh signaling is required to
maintain proliferation. Finally, no proliferation changes were
observed at HH 18 after cyclopamine treatment, which corresponds
to when Ptc2 expression appears to decrease (Supplementary Fig
1). Together, these data show that cyclopamine requires more than. (A) HH 16 control embryo and (B) HH 16 embryo treated with 0.6 μg/μl CPA at HH 14.
U-positive cells counted in 10-cell increments at HH 15 to 18. SHF cells were counted
a myocardial marker (red) in (A) and (B), and moving caudally through the splanchnic
in the SHF adjacent to the pharyngeal endoderm (the caudal-most 30 cells) occurs at
treatment (HH 16), proliferation is no longer increased in the caudal SHF (pb0.01 for
. By HH 18, no differences are observed in CPA-treated embryos compared to control
310 L.A. Dyer, M.L. Kirby / Developmental Biology 330 (2009) 305–3176 h to reduce proliferation and that this reduction is lost within
24 h of exposure.
To determine whether decreased proliferation was accompanied
by increased cell death, apoptosis was analyzed in the secondary heart
ﬁeld at HH 16. While an occasional cell in the secondary heart ﬁeld
was apoptotic, cyclopamine treatment did not induce secondary heart
ﬁeld apoptosis (Supplementary Fig 2).
Cyclopamine induces pulmonary atresia and stenosis
Abnormal proliferation in secondary heart ﬁeld progenitors has
been linked to arterial pole defects in other models (Hutson et al.,
2006; Waldo et al., 2005b; Xu et al., 2004), suggesting that
cyclopamine treatment may result in arterial pole defects later in
development. Because the secondary heart ﬁeld contributes myo-
cardium early, at HH 14, and smooth muscle later, at HH 18,
embryos were treated at both stages and allowed to develop to HH
35. Seventy-eight percent of hearts treated at HH 14 had a single
outﬂow vessel (n=32, Fig. 4) with anomalous great arteries. In
chick, the bilaterally symmetrical pharyngeal arch arteries remodel
into a right-sided aorta, giving rise to a right and left brachioce-
phalic artery, and a left and right ductus arteriosus. Cyclopamine-
treated embryos exhibited a range of remodeling defects, with two
to four vessels branching off the single outﬂow vessel; the
brachiocephalic arteries were identiﬁable, and the extra vessels
were likely abnormally persistent pharyngeal arch arteries. The
origin of the brachiocephalic arteries (derived from pharyngeal arch
artery 3) was shifted to the right side of the outﬂow vessel, giving a
twisted appearance. In addition, disrupting Shh at HH 14 resulted in
peripheral edema of varying severity (11 of 32 treated embryos);Fig. 4. Cyclopamine (CPA) treatment induces arterial pole defects. (A) PBS-treated control; (B
HH 18. Embryos treated at HH 14 show a range of defects, but all have a single outﬂow vessel
proximal to the ventricles. Histological analysis identiﬁed the single vessel. The single vesse
Embryos treated at HH 18 (C) are morphologically indistinguishable from controls. PT, pulmoccasionally, the right eye was small (n=3), or the forelimbs were
truncated (n=8).
Disruption of Shh at HH 18 (n=3) with the highest dose of
cyclopamine (1.0 μg/μl) resulted only in mild edema (n=1) and
limb defects (n=2); embryos looked normal, and no gross heart
abnormalities were observed. Because treatment at HH 18 resulted
in normal embryos, embryos were treated at additional stages to
determine when they were most sensitive to Shh signaling. Embryos
treated before HH 14 had a high incidence of lethality (33% of
embryos treated at HH 12–13 survived to HH 34); all surviving
embryos had a single outﬂow vessel (Supplementary Table 1).
Embryos treated at HH 15 and 16 had better survival to HH 35 (80%
survived to HH 35) and a reduced incidence of single outﬂow
vessels (32.5%; Supplementary Table 1).
To distinguish between PTA and pulmonary atresia in cyclopa-
mine-treated embryos, hearts were sectioned to conﬁrm the
identity of the single outﬂow vessel. The distinction between PTA
(a common aortic and pulmonary vessel) and pulmonary atresia
(only an aortic outﬂow) was made in serial sections by following
the origins of both the pulmonary and systemic outﬂows from the
ventricles through the outﬂow vessel. The pulmonary infundibulum,
which gives rise to the pulmonary outlet, was narrow (Fig. 5B) or
hypoplastic below the semilunar valves in four embryos (see Table 2
for a breakdown by dosage); the pulmonary outlet was atretic at the
semilunar valves in another nine embryos. Blood would have ﬂowed
from the right ventricle via a ventricular septal defect (Fig. 5B)
through a single vessel with a semilunar valve; based on the atretic
right ventricular outﬂow, these 13 embryos were conﬁrmed to have
pulmonary atresia. Pulmonary stenosis was present in two embryos,
one below and the other at the semilunar valves. PTA was seen in), (D), hearts treated with 0.6 μg/μl CPA at HH 14; (C) heart treated with 1.0 μg/μl CPA at
, and the origins of the great arch arteries are shifted to the right side and originate more
l in (B) is an aorta (Ao); the single vessel in (D) is persistent truncus arteriosus (PTA).
onary trunk; RB, right brachiocephalic; LB, left brachiocephalic. Scale bar is 175 μm.
Fig. 5.Histological analysis of HH 35 hearts. (A, Aq) PBS-treated control; (B–Cq) hearts treated with 0.6 μg/μl CPA at HH 14; (D–Dq) heart treated with 1.0 μg/μl at HH 18. In the control
heart (A), the aortic vestibule (AoV) and pulmonary infundibulum (PI) are separated (A) and about the same size. At the valve level, two robust arterial trunks can be seen in the
correct orientation. The aorta (Ao) is identiﬁed based on its origin from the AoV (A), its posterior position relative to the pulmonary artery (P) at the valve level (A'), and the presence
and position of two coronary artery stems from the coronary sinuses (arrows in Aq). After CPA treatment at HH 14 (B), a ventricular septal defect allows a connection between the
small PI and the AoV (B). The PI disappears before reaching the single outﬂow vessel (B'). The presence of two coronary arteries penetrating the single outﬂow vessel further conﬁrms
the identity of the Ao (arrows in Bq), indicating that this embryo had pulmonary atresia. Another embryo treated at HH 14 (C) exhibits pulmonary atresia. While a ventricular septal
defect is present, this defect is very high. The single outﬂow vessel has ﬁve valve leaﬂets (C'); in addition, two coronary arteries penetrate the aortic side of the single outﬂow vessel,
one of which is seen in Cq (arrow). Treatment at HH 18 (D) results in a well-formed ventricular septum (D), divided arterial valves, (D') and normal coronary arteries (arrows in Dq).
Scale bar is 250 μm in A, A' and 100 μm in Aq; the same scales apply to rows B–D.
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atresia based on the position of the single outﬂow vessel, which was
oriented over the ventricular septum, and the pulmonary infundi-
bulum being equivalent in size to the aortic vestibule (Fig. 5C). The
last two treated embryos had a single outﬂow vessel that could not
be identiﬁed as either pulmonary atresia or PTA.
The designation of pulmonary atresia as opposed to PTA was
further conﬁrmed by identifying the number of semilunar valve
leaﬂets and the position of the coronary arteries. The aorta and
pulmonary trunks normally have three valve leaﬂets each. In
embryos classiﬁed as having pulmonary atresia (n=13), the
semilunar valve of the presumptive aorta had three leaﬂets in 11
embryos (5Bq); one semilunar valve had two leaﬂets, and the
number of leaﬂets could not be clearly deﬁned in the remaining
embryo. In embryos classiﬁed as having PTA (n=8), the singleoutﬂow vessel had between three and ﬁve semilunar valve leaﬂets,
in agreement with Williams et al. (1999). In one embryo with three
leaﬂets, the valve leaﬂets were abnormally large, and two leaﬂets
were poorly separated.
The location of the coronary arteries was critical in designating
pulmonary atresia as opposed to PTA. After cyclopamine treatment,
some embryos were missing either the left or right coronary artery
(n=1 for each side), and in other embryos, the coronary arteries were
either abnormally large or the vascular plexus failed to coalesce into
two distinct stems (n=8); these data suggest that secondary heart
ﬁeld-derived smooth muscle is also disrupted after cyclopamine
treatment. However, the coronary arteries that were present in
embryos classiﬁed as having pulmonary atresia arose from the single
outﬂow vessel in the normal orientation (Fig. 5Bq), conﬁrming the
identity of the single vessels as aortas. In contrast, the coronary
Table 2
Embryos treated atHH14with eitherdose of cyclopaminewere signiﬁcantly different from
control embryos (p=2.4×10−8) and each other (p=0.04), as determined with Fisher's
exact test.
Phenotype Control
(n=13)
0.6 μg/μl CPA
(n=16)
0.8 μg/μl CPA
(n=14)
Hypoplastic pulmonary
infundibuluma
0 3 1
Atretic pulmonary outleta 0 6 3
Stenotic pulmonary outlet 0 2 0
Persistent truncus arteriosus 0 2 6
Unidentiﬁable single outlet 0 1 1
Normal 13 2 3
a Both of these phenotypes were classiﬁed as pulmonary atresia based on the absence
of a pulmonary artery.
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approximately where they would penetrate the systemic half of the
common trunk (Fig. 5Cq).
In addition to these defects, 80% of the cyclopamine-treated
embryos (n=30) had ventricular septal defects, whereas a
ventricular septal defect was present in only one control embryo
(n=13).
Embryos treated with cyclopamine before HH 14 had either
pulmonary atresia (n=2) or PTA (n=1) (Supplementary Table 1).
One embryo treated at HH 13 had too many coronary arteries (one in
each of four valve leaﬂets). Embryos treated at HH 15 and 16 also
exhibited both pulmonary atresia (n=1) and PTA (n=2). One
embryo treated at HH 15 had poorly coalesced coronary vessels, and
one embryo treated at HH 16 was missing a coronary artery. Embryos
treated at HH 18 (Figs. 5D–Dq) had intact ventricular septa, normally
aligned aorta and pulmonary trunk outlets, and two distinct coronary
arteries that penetrated the aortic wall. The secondary heart ﬁeld
begins providing smooth muscle to the arterial pole at HH 18.
However, no coronary artery abnormalities were seen after cyclopa-
mine treatment at this stage, which suggests that the coronary artery
anomalies seen in embryos treated at HH 14 are related to the
proliferation defect observed at HH 16–17.
Altogether, these defects indicate that the pulmonary outlet is
particularly sensitive to secondary heart ﬁeld proliferation, which is
supported by hedgehog signaling. The secondary heart ﬁeld can be
affected between HH 12 and HH 16, although it becomes less sensitive
after HH 14, and inhibiting Shh signaling at any one particular stage
does not favor pulmonary atresia over PTA. However, these results do
not explain the twisted brachiocephalic arteries or the persistent arch
arteries, suggesting that either the cardiac neural crest-derived cells
were also affected or the aortic arch arteries are also directly affected
by hedgehog signaling.
Arch artery patterning
The pharyngeal arch arteries form as bilaterally symmetrical
pairs as the outﬂow tract gathers myocardium from the secondary
heart ﬁeld. At HH 18, arch arteries 1–3 are open, and arch artery 4
is forming; by HH 19, the ﬁrst arch artery has regressed, and arch
artery 4 has lumenized. Arch arteries 5–6 begin to form at HH 20,
and when arch artery 6 is patent by HH 23, arch artery 2 has
regressed. Arch artery 5 is present only brieﬂy at HH 22. Starting at
HH 28, asymmetrical remodeling begins, and the left fourth arch
artery closes (Hiruma and Hirakow, 1995). Once remodeling is
complete, the arch arteries are referred to as the great arteries of
the thorax. To follow the development of the arch arteries, we
injected India ink into cyclopamine-treated embryos. Based on the
different phenotypes induced by varying doses of cyclopamine,
0.6 μg/μl was selected to favor pulmonary atresia as an outcome.
At HH 18, the pharyngeal arch artery pattern looked similar
between control and treated embryos; however, the ﬁrst archartery had begun regressing in the control embryo (Fig. 6A),
whereas it was still robust in the treated embryo (Fig. 6B). The
ﬁrst and second arch arteries occasionally persisted as late as HH
22–23 (data not shown). By HH22–23, the fourth and sixth arch
arteries should appear (Fig. 6C), but the right fourth and sixth arch
arteries developed abnormally after cyclopamine treatment (Fig.
6D). However, most ink-injected embryos at HH 29 showed the
correct patterning of the arch artery derivatives (Fig. 6F). The left
fourth arch artery had apparently closed, as in the controls, leaving
left arch arteries 3 (left brachiocephalic) and 6 (right ductus
arteriosus) and right arch arteries 3–6 (right brachiocephalic, aortic
arch, and ductus arteriosus) (75%; n=4). One treated embryo had
only two great arteries present on each side, and these arteries
appeared to be arteries 3 and 6 in whole mount. In all four HH 29
embryos, the arteries were longer, with kinks; despite the early
abnormalities, the overall patterning appeared normal after the
remodeling stage.
The HH 29 ink-injected hearts were sectioned to conﬁrm this
apparently normal cardiovascular phenotype of cyclopamine-treated
embryos. In transverse sections through PBS-treated control
embryos, the expected arch arteries were present; left arch artery
3 and right arch arteries 3 and 4 branched off the aortic trunk, and
both left and right arch arteries 6 joined the pulmonary trunk (Fig.
7B). These two trunks were clearly separated at the level of the
outﬂow tract valves (n=4), and the interventricular septum was
intact. In cyclopamine-treated embryos, almost all right-sided arch
arteries appeared normal (n=4); however, one embryo lacked both
the right and left sixth arch arteries and maintained both fourth
arch arteries instead. In this case, the left fourth arch artery
connected to the heart where the pulmonary trunk would originate.
In another embryo, a remnant of the left fourth arch artery
remained, and the left and right sixth arch arteries branched off
the dorsal aorta at the same level. In the remaining two embryos,
the second open artery on the left side was not clearly the fourth or
sixth arch artery (50%). This arch artery (designated 4/6 in Fig. 7B)
connected to the heart where the pulmonary trunk should originate.
While these cyclopamine-treated embryos showed a diverse range
of phenotypes, most of the defects speciﬁcally affect pulmonary
trunk and sixth arch artery development. These defects suggest that
the cardiac neural crest, which invests and repatterns the
pharyngeal arches, may also be disrupted.
Cardiac neural crest migrate to the outﬂow tract cushions
In order to determine whether cardiac neural crest-derived cells
migrate into the pharyngeal arches and outﬂow tract in embryos
with pulmonary atresia, we evaluated cyclopamine-treated quail-
chick chimeras. By using the 0.8 μg/μl cyclopamine dose, which
gave rise to a large percentage of PTA, we could also determine
whether PTA was a primary neural crest defect or a secondary
effect based on the initial secondary heart ﬁeld defect. Quail-chick
neural crest chimeras were treated with cyclopamine at HH 14 and
incubated until HH 23–24, when cardiac neural crest-derived cells
reach the outﬂow tract cushions. Quail cells were seen surrounding
the arch arteries (data not shown). Quail cells also entered the
outﬂow tract cushions and were seen in two distinct prongs (n=3,
Figs. 8A, B). The two prongs were unequal in size, but the pattern
was normal (Kirby et al., 1983). The quail neural crest-derived cells
that entered the outﬂow tract were not dying, as indicated by an
absence of TUNEL-positive quail cells. This result is consistent with
the work of Lin et al. (2006), who showed that cardiac neural
crest-derived cells migrate into the outﬂow tract in conditional
knockouts that eliminated hedgehog signaling from Isl-1 expressing
cells.
Interestingly, the cardiac neural crest-derived cells form an
outﬂow tract septum but do not symmetrically divide the outﬂow
Fig. 6. India ink injections of PBS- (A, C, E) and cyclopamine (CPA)-treated (B, D, F) embryos. CPA-treated embryos at HH 18 (B) have a persistent ﬁrst arch artery, compared to the
control (A), where it has begun to regress. In addition, the junction between the aortic sac and the outﬂow tract is widened after CPA treatment. By stage HH 22–23, arch arteries 3, 4,
and 6 are normally open (C); however, after CPA treatment, pharyngeal arch arteries 4 and 6 are very small (thin endothelial strands marked with arrows in D). Right arch arteries 4
and 6 are so thin that the left arch arteries are visible, unlike in the control. At HH 29, the appropriate pharyngeal arch arteries appear to be present (compare cyclopamine-treated F
with control E). Arch arteries are labeled according to arch number and side. Scale bar is 100 μm.
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complete, the septum formed closer to the pulmonary side of the
arterial trunk in cyclopamine-treated chimeras (n=2). The identity
of the aorta was also conﬁrmed by the presence of coronary
arteries, which arose from the aortic wall. The presence of cardiac
neural crest-derived cells indicates that pulmonary atresia is not
associated with a failure of outﬂow tract septation. No chimeras
were observed with PTA, precluding the possibility of determiningwhether the cardiac neural crest are present in the outﬂow tract in
PTA associated with cyclopamine treatment. Together, these results
show that cardiac neural crest migration and survival are not
affected by hedgehog signaling between HH 14 and HH 18 and
suggest that the sixth aortic arch artery abnormalities may instead
be caused by direct effects of hedgehog signaling on the
pharyngeal arches. Increased apoptosis observed in the caudal
arches at HH 16, when neural crest cells have not yet populated
Fig. 7. Sectioned India ink-injected embryos at HH 29. A–D, PBS-treated embryo; E–H, CPA-treated embryo. In the control, the left fourth arch artery (L4) is regressing (B), and a
septum is beginning to divide the outﬂow tract (D). In the CPA-treated embryo, the left 4/6 arch artery (L4/6) is not at the level of either the fourth or sixth arch (E–F), and an open
communication persists between the pulmonary (P) and aortic (A) trunks (arrow, H). Arch arteries are labeled according to arch number and side. Scale bar is 200 μm.
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Fig 2).
Discussion
Shh-null mice exhibit extensive defects (Litingtung et al., 1998;
Tsukui et al., 1999; Chiang et al., 2001), and the heart displays a
broad range of malformations, including pulmonary atresia, atrial
and ventricular septal defects, and atrioventricular valve defects
(Washington Smoak et al., 2005). Tissue-speciﬁc knockout mice
have shown that the pharyngeal endoderm is the critical source of
Shh for heart development (Goddeeris et al., 2007), but even in
these mice, the cardiac neural crest cells die in the pharyngeal
arches. This additional defect complicates the issue of how Shh can
affect a discrete population of cells, such as the secondary heart
ﬁeld, independent of other populations, such as the cardiac neural
crest.
The present study avoids many other defects by inhibiting
hedgehog signaling in a temporally discrete fashion.While application
of hedgehog inhibitor cyclopamine was performed globally, it has a
short period of activity (less than 24 h), reducing its ability to
inﬂuence other aspects of heart development. Few defects were found
outside of the heart, and heart defects were limited to the arterial pole.
Blocking hedgehog signaling in secondary heart ﬁeld explants slightly
reduced migration and dramatically reduced proliferation. By apply-
ing cyclopamine in ovo at the onset of the myocardial contribution
from the secondary heart ﬁeld to the outﬂow tract, we showed that
the arterial pole defects were linked to a localized decrease in
secondary heart ﬁeld proliferation. Blocking Shh after the myocar-
dium has been added to the outﬂow tract (HH 18) resulted in normal
heart development. Because inhibiting this signaling pathway has
such a pronounced effect, the timing of Shh signaling must be critical
and tightly regulated in order to maintain the correct rate of
proliferation and migration.
The secondary heart ﬁeld remains a pool of undifferentiated
progenitors until these cells migrate into the outﬂow tract and
differentiate (Waldo et al., 2001). Nkx2.5 and Isl1 demarcate the initial
bilateral heart ﬁeld, and continued expression of these markers is
associated with the pool of proliferative progenitors (Prall et al., 2007
and Cai et al., 2003). Additionally, Isl1 induces Shh expression in the
pharyngeal endoderm (Lin et al., 2006) and proliferation in the
splanchnic mesoderm of the second heart ﬁeld (Cai et al., 2003).Eliminating the downstream signaling component Smoothened
(Smo) from Isl1-positive cells causes PTA and pharyngeal arch
patterning defects (Lin et al., 2006), both of which are seen after
cyclopamine treatment in this study. β-catenin is also required for
proliferation of Isl1-positive cardiac progenitors andmay regulate Shh
in the foregut endoderm (Lin et al., 2007). The overlapping signaling
factors required to maintain proliferation must be tightly regulated
because the secondary heart ﬁeld fails to migrate into the arterial pole
if too much (Waldo et al., 2005b) or too little (Xu et al., 2004 and this
paper) proliferation occurs.
Shh is upstream of cell cycle genes that control both the G1-S
transition, such as cyclins D1 and E (Kenney and Rowitch, 2000)
and n-myc (Oliver et al., 2003), and the G2-M transition, such as
CDC25B (Benazeraf et al., 2006). The effect of Shh on CDC25 is a
non-cell autonomous effect, which is consistent with the ﬁnding
that the secondary heart ﬁeld can respond to Shh produced in the
pharyngeal endoderm. Interestingly, Shh is incapable of recruiting
quiescent neuronal cells into the cell cycle (Kenney and Rowitch,
2000). If Shh similarly cannot induce terminally differentiated cells
to proliferate, this datum would suggest that Shh would only be
able to maintain proliferation in non-differentiated myocardial
precursors. Shh also deﬁnes the mitogenic niche for cerebellar
granular cells (Choi et al., 2005); when neuronal precursors migrate
away from the source of Shh, proliferation decreases. The caudal
secondary heart ﬁeld might serve as a niche that holds cells in a
proliferative state until either they migrate into the outﬂow tract or
the outﬂow tract is displaced caudally with respect to the
pharyngeal arches and comes in close enough proximity to initiate
a differentiation signaling cascade.
Interestingly, BMP2 is expressed in the outﬂow tract and promotes
differentiation (Waldo et al., 2001). In addition, it speciﬁcally inhibits
Shh-induced proliferation by down-regulating n-myc expression
(Alvarez-Rodriguez et al., 2007), supporting the idea of a proliferative
niche within the secondary heart ﬁeld that is distinct from the
migratory secondary heart ﬁeld that is entering the outﬂow tract and
in close proximity to BMP2.
Laser ablation of the right side of the secondary heart ﬁeld, which
physically reduces the number of cells that can contribute to the
outﬂow tract, results in pulmonary stenosis and atresia (Ward et al.,
2005). Reducing proliferation in the secondary heart ﬁeld by applying
cyclopamine could also result in fewer cells that can contribute to the
arterial pole. Using amouse Tbx1 hypomorph, Xu et al. (2004) showed
Fig. 8. Quail-chick chimeras treated with PBS (A, C, E) and cyclopamine (CPA, B, D, F) show that the cardiac neural crest enter and septate the outﬂow tract (OFT). Apoptosis was
analyzed before septation (HH 23–24, A, B). In both control (A) and cyclopamine-treated (B) chimeras, the quail neural crest-derived cells (green) are not TUNEL-positive (red) as
they enter the OFT, indicating that these cells are not undergoing apoptosis. Nuclei are counterstained with DAPI (blue). Of note, the aortic outlet (AO) is open in both control (A) and
CPA-treated (B) embryos; the pulmonary outlet (PO), though, is only open in the control embryo (A). After septation occurs (HH 35, C–F), the presence of quail neural crest-derived
cells in the outﬂow tract was conﬁrmed (red in C and close-up E; green in D and close-up F), and embryos were co-labeled with either myocardial marker MF20 (red in panels D and
F) or smooth muscle marker SM22-α (green in panels C and E). Quail neural crest-derived cells are still present after CPA treatment (D); however, these cells do not form two equal-
sized outﬂow vessels as seen in the control (C). Instead, the prominent outﬂow vessel in the CPA-treated chimera is the aorta (A), as determined by connection to the ventricles and
the presence of a coronary artery; a small pulmonary (P) is septated by the quail neural crest-derived cells (highlighted with an arrow in panel D). The close-ups in panels E and F
suggest that there may be a cell size difference after CPA treatment. C–F are co-labeled with DAPI. Scale bar is 100 μm in A–D and 50 μm in E, F.
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suggested a correlation between secondary heart ﬁeld proliferation
and its myocardial contribution to the outﬂow tract. Like the
cyclopamine-treated chick, this mouse mutant predominantly exhi-
bits a single outﬂow vessel, and the pulmonary infundibulum is
reduced in size; in some of these embryos, the single outﬂow vessel
sits over the ventricular septal defect, but in others, this vessel arises
predominantly from the left ventricle and looks more like an aorta
than a common trunk (Théveniau-Ruissy et al., 2008). Cardiac neural
crest-derived cells still migrate into the pharyngeal arches, although at
reduced levels in the fourth arches. Our studies show that neuralcrest-derived quail cells still migrated into the outﬂow tract cushions
of cyclopamine-treated chick embryos and formed a septum that was
positioned incorrectly, effectively closing off the pulmonary outlet and
resulting in pulmonary atresia.
In cyclopamine-treated embryos, pulmonary stenosis, pulmonary
atresia, and PTA are all observed. There are a few ways that this
range of defects can occur. The ﬁrst is that the outﬂow tract
myocardium produces signals that serve as a chemoattractant,
encouraging the cardiac neural crest-derived cells to migrate into
the cushions. Less myocardium would then secrete less chemoat-
tractant and may only weakly attract the cardiac neural crest-
316 L.A. Dyer, M.L. Kirby / Developmental Biology 330 (2009) 305–317derived cells. However, normal numbers of cardiac neural crest-
derived cells were observed in the outﬂow tract cushions after
hedgehog inhibition, making this possibility unlikely. Alternatively,
intrinsic differences between aortic and pulmonary myocardium
may set up a target for the cardiac neural crest-derived cells as they
migrate into the outﬂow tract (Bajolle et al., 2008); a speciﬁc
reduction in pulmonary myocardium would then result in the
septum forming asymmetrically, as was observed in the present
study. One could speculate that Shh has a left–right effect on the
secondary heart ﬁeld, similar to its earlier role as the ﬁrst left-
restricted gene during chick embryogenesis (Levin et al., 1997); a
sided effect would explain why the pulmonary trunk was more
severely affected. Shh is upstream of left-restricted Pitx2c in the
early lateral plate mesoderm (St.Amand et al., 1998), and Pitx2c is
restricted to the left secondary heart ﬁeld at E9.5 in mouse, which is
at the end of the myocardial contribution (Liu et al., 2001).
However, no other genes have been shown to have left–right
asymmetry in the secondary heart ﬁeld. Because the defects seen
after cyclopamine treatment predominantly affect the pulmonary
trunk, which is derived from the right side of the secondary heart
ﬁeld, it would be interesting to determine whether there is a right-
sided transcription factor or signaling pathway that is altered after
cyclopamine treatment. This possibility, though, does not address
what causes PTA.
Because PTA, which is caused by a failure of cardiac neural crest-
derived cells to septate the outﬂow tract, was favored in embryos
treated with 0.8 μg/μl cyclopamine, quail-chick chimeras were treated
with this dose in order to determine whether the cardiac neural crest
was directly affected. However, cardiac neural crest-derived cells
migrated into the pharyngeal arches and the outﬂow tract cushions
and did not undergo apoptosis. Despite the predominant PTA
phenotype observed with this cyclopamine dose, the cardiac neural
crest cells migrate normally and survive. However, the cardiac neural
crest-derived cellsmaynot behavenormally once reaching the outﬂow
tract. Another possibility is that not enough cardiac neural crest-
derived cells populate the outﬂow tract, resulting in either a smaller
septum that divides the outﬂow tract unequally or fails to septate the
outﬂow tract at all.
The cyclopamine-induced defects seen after outﬂow tract septa-
tion occurs are likely caused by reducing the number of secondary
heart ﬁeld progenitors. This decrease results in both fewer myocardial
and smooth muscle cells. The role of Shh in maintaining proliferation
is critical, but other factors must contribute to this regulation. Further
work will be necessary to tease apart the factors that control regional
proliferation to better understand how the secondary heart ﬁeld
contributes to the arterial pole and how this contribution is miscued
during heart malformations.
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